18 November 2019

Verona Pharma plc: PDMR Dealing – Purchase by Chairman

LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr. David Ebsworth, Chairman of the Company, has notified the Company that he has purchased a further 25,000 ordinary shares of 5 pence each in the Company (“Ordinary Shares”) at a total purchase price of £11,750, at a price of 47 pence per Ordinary Share. This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £125,000.

Following the purchase, Dr. Ebsworth will have an interest in the Company of 395,387 Ordinary Shares, representing 0.38% of the Company’s issued share capital.

Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1Details of the person discharging managerial responsibilities/person closely associated
a)NameDavid Ebsworth
2Reason for the notification

a)

Position/status
Chairman
b)Initial notification/AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerona Pharma plc
b)LEI

 
213800EVI6O6J3TIAL06

 


4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)Description of the financial instrument, type of instrumentOrdinary Shares of 5 pence each 
Identification codeGB00BYW2KH80 
b)Nature of the transactionDavid Ebsworth purchased 25,000 Ordinary Shares 
 
c)Price(s) and volume(s)Price(s)Volume(s) 
47 pence 25,000 
  
d)Aggregated informationN/A 
-  Aggregated volume 
-  Price 
e)Dates of the transactions14-Nov-19 
f)Place of the transactionsLondon Stock Exchange, AIM 
     


For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officerinfo@veronapharma.com
Victoria Stewart, Director of Communications 
  
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 3283 4200
Aubrey Powell / George Tzimas (Corporate Finance) 

Mia Gardner (Corporate Broking)

 


For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us